Bladder Cancer Therapeutics Market Trend, Growth, Analysis, Opportunities Demand, Size and Share and Future Forecast 2018 - 2026
![]() |
Bladder cancer is characterised by abnormal growth of tissues in the bladder's inner layer. These abnormal tissues are known as tumours, and they have the potential to spread to nearby tissues or muscles. Bladder cancer is the ninth most common type of cancer in men and women worldwide, with the highest recurrence rate. There are two types of bladder cancer: muscle-invasive and non-muscle-invasive. The most common type of bladder cancer is non-muscle-invasive bladder cancer, which is less fatal. It is also known as superficial bladder cancer because the tumour grows inside the bladder lining. Muscle-invasive bladder cancer occurs when the tumour spreads beyond the bladder lining. This type of bladder cancer is extremely rare and deadly.
The standard treatment for non-muscle-invasive bladder cancer is transurethral resection of the tumour, followed by perioperative chemotherapy. Due to the cancer's recurrence, patients must have yearly checkups. Although there has been significant progress in bladder cancer treatment over the last decade, there are still significant unmet needs. The prevalence of bladder cancer, as well as growing awareness about its various types and treatments, are major factors driving the significant growth of the global bladder cancer treatment drugs market.
Technological advancements, innovative treatments, advanced health care services, increased public awareness of cancer therapies, and rising health-care expenditures will drive the bladder cancer therapeutics market globally. However, the high costs of bladder cancer therapies and the disease's asymptomatic nature may limit market growth. However, factors such as the increasing influence of targeted biologics, the introduction of novel drugs, and the acceptance of effective diagnostic tools may drive demand for the global bladder cancer therapeutics market.
The major companies playing key role in bladder therapeutics market are Sanofi S.A., F. Hoffmann-La Roche AG, Novartis, Pfizer, Eli Lilly and Co., GlaxoSmithKline, Bristol-Myers Squibb, Allergan Inc., AVI Biopharma Inc., and AstraZeneca plc. Some are the major drugs approved by Food and Drug Administration used for the treatment of bladder cancer are Cisplatin, Nivolumab, Thiotepa, Atezolizumab, Doxorubicin Hydrochloride, Opdivo (Nivolumab), Platinol-AQ (Cisplatin), Platinol (Cisplatin), and Tecentriq (Atezolizumab).
Comments
Post a Comment